Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
SAN FRANCISCO , Oct. 31, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on Tuesday, November 7, 2023, after the close of U.S.-ba
Nektar (NKTR), Cellular Biomedicine Join for Lung Cancer Studies
09:01am, Thursday, 28'th Sep 2023
Nektar (NKTR) enters into a deal with Cellular Biomedicine Group to develop NKTR-255 in combination with C-TIL05 to treat advanced NSCLC.
Nektar (NKTR) Up on Positive New Data From Eczema Study
09:01am, Thursday, 14'th Sep 2023
Nektar (NKTR) gains on positive new data for its pipeline candidate, rezpegaldesleukin, evaluated from an early-stage study for treating atopic dermatitis.
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
01:05pm, Wednesday, 13'th Sep 2023
Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
02:22pm, Monday, 11'th Sep 2023
Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with th
5 Top-Ranked Stocks With Rising P/E for Solid Returns
09:46am, Thursday, 24'th Aug 2023
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ)
Nektar (NKTR) Stock Surges 75% in a Week: Here's Why
01:09pm, Monday, 14'th Aug 2023
Nektar's (NKTR) shares rally almost 75% in a week on corrected efficacy data for rezpeg studies, earlier miscalculated by Eli Lilly.
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
10:42am, Wednesday, 09'th Aug 2023
Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.
Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript
10:58pm, Tuesday, 08'th Aug 2023
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - Preside
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
06:56pm, Tuesday, 08'th Aug 2023
Nektar Therapeutics (NKTR) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.85 per share a year ago.
Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment
11:30am, Monday, 07'th Aug 2023
Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.
Nektar rallies after releasing new data for rezpeg after Eli Lilly got it wrong
08:10am, Monday, 07'th Aug 2023
Nektar Therapeutics (NASDAQ:NKTR) shares rallied more than 15% in Monday pre-market trading after the company released new efficacy data from phase 1b studies from rezpegaldesleukin (rezpeg) after th
Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its
SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-base
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
06:00pm, Monday, 12'th Jun 2023
SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Glo
